{
  "source": "PA-Notification-Bronchitol.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1353-5\nProgram Prior Authorization/Notification\nMedications Bronchitol® (mannitol)\nP&T Approval Date 3/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nBronchitol is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary\nfunction in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only in\nadults who have passed the Bronchitol Tolerance Test.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Bronchitol will be approved based on all of the following criteria:\na. Diagnosis of cystic fibrosis (CF)\n-AND-\nb. Used in conjunction with standard CF therapies [e.g., chest physiotherapy,\nbronchodilators, antibiotics, anti-inflammatory therapy (e.g., ibuprofen, oral/inhaled\ncorticosteroids)]\n-AND-\nc. Patient has passed the Bronchitol Tolerance Test\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Bronchitol will be approved based on the following criteria:\na. Documentation of positive clinical response to Bronchitol therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program.\n• Supply limitations may be in place.\n4. References:\n1. Bronchitol [package insert]. Cary, NC: Chiesi USA, Inc.; January 2024.\nProgram Prior Authorization/Notification - Bronchitol (mannitol)\nChange Control\n3/2021 New program.\n3/2022 Annual review with no change to coverage criteria.\n3/2023 Annual review. Clarified ",
    "ary 2024.\nProgram Prior Authorization/Notification - Bronchitol (mannitol)\nChange Control\n3/2021 New program.\n3/2022 Annual review with no change to coverage criteria.\n3/2023 Annual review. Clarified that “CF” refers to cystic fibrosis without\nchange to clinical intent. Added state mandate.\n3/2024 Annual review. No change to coverage criteria. Updated reference.\n3/2025 Annual review. No change to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}